

**ASX Announcement | 2 July 2021**  
**Visioneering Technologies (ASX:VTI)**

**Visioneering Technologies, Inc. Welcomes Industry Leader Dwight Akerman, OD, MBA, FAAO as Independent Director**

**Atlanta, Georgia, USA 1 July 2022:** Visioneering Technologies, Inc (ASX: VTI), a US-based medical device company ('Visioneering' or 'The Company') engaged in the design, manufacture, sale, and distribution of its proprietary NaturalVue™ Multifocal 1 Day (NaturalVue MF) contact lenses, is pleased to announce the appointment of Dr. Dwight Akerman to its Board of Directors, and as Chairman of the Science and Technology Committee of the Board.

Dr. Akerman is an optometrist and an experienced executive in the vision care industry, with 41 years of leadership in eye care, new product development, clinical and regulatory affairs, academic and professional affairs, business development and licensing, and executive management. He is currently the Chief Medical Editor of "Review of Myopia Management" and recently retired from Alcon as Vice President and Global Head of Professional Affairs and Business Development.

Dr. Akerman served several roles over his career at contact lens and vision care leader CIBA Vision prior to CIBA Vision's merger with Alcon. From 2001 to 2011 at CIBA Vision, he served as Director of Marketing, Director of Professional Affairs in North and South America, and Global Head of Medical Affairs at Novartis Ophthalmics. After CIBA Vision merged with Alcon, Dr. Akerman served as Executive Director of US Professional Affairs before being promoted to Vice President and Global Head of Professional Affairs and Business Development. In this final role at Alcon, Dr. Akerman was a member of the vision care global leadership team and had responsibilities for myopia management strategy, medical marketing, business development and licensing, and managed the company's relationship with global medical associations.

Prior to his tenure at Alcon, Dr. Akerman was Director of Global Clinical Research and Professional Affairs for 10 years at Wesley Jessen Corp., which merged with CIBA Vision in 2001.

Dr. Akerman is also an accomplished practitioner, having operated optometric practices for 10 years prior to entering corporate management. He earned his Doctor of Optometry degree at the Illinois College of Optometry and his MBA at the University of Texas at Tyler.

On behalf of the Board of Directors, **Visioneering's CEO, Dr. Stephen Snowdy**, and its **non-executive Chairman, Dr. David J. Mazzo**, jointly said, "Dr. Akerman is a globally recognized contact lens industry executive and myopia management expert. We welcome Dwight to the VTI Board of Directors and expect that his combination of technical expertise, business development experience, and industry relationships will serve the shareholders well."

**Ends.**

**This release was authorized by the CEO, Stephen Snowdy, PhD.**

**For more information, please contact:**

Stephen Snowdy, PhD  
CEO and Executive Director  
[ssnowdy@vtivision.com](mailto:ssnowdy@vtivision.com)

### **About Visioneering Technologies**

Visioneering Technologies Inc. (ASX:VTI) is a health care company making innovative vision care products available to patients and eye care professionals. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing, and regulatory leaders from the healthcare industry to provide new solutions for adults and children in need of vision correction.

Headquartered in the United States, Visioneering designs, manufactures, sells, and distributes contact lenses worldwide. Its flagship product, NaturalVue® Multifocal contact lenses, are prescribed in the large addressable markets of nearsighted children and over-45 adults, and VTI is expanding its portfolio of technologies to address a range of other vision care needs. Since its IPO in 2017, the company has grown operations across the US and recently launched its products in Australia, New Zealand, Singapore, Hong Kong, Canada, and Europe.

### **Foreign ownership restrictions**

VTI's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, plans and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX49